Tertiary patenting on drug–device combination products in the United States

Drug–device combination products are becoming increasingly prevalent, with many lasting years beyond the expiration date of primary and secondary patents on the drug itself.

Saved in:
Bibliographic Details
Published in:Nature biotechnology 2018-02, Vol.36 (2), p.142-145
Main Authors: Beall, Reed F, Kesselheim, Aaron S
Format: Article
Language:English
Subjects:
Agriculture
Anaphylaxis
Bioinformatics
Biomedical and Life Sciences
Biomedical Engineering/Biotechnology
Biomedicine
Biotechnology
Drug delivery systems
FDA approval
Federal regulation
Inhalers
Intellectual property
Life Sciences
Manufacturers
Price increases
Product recalls
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Drug–device combination products are becoming increasingly prevalent, with many lasting years beyond the expiration date of primary and secondary patents on the drug itself.
ISSN:1087-0156
1546-1696
DOI:10.1038/nbt.4078